Skip to Content

Cancer Research & Clinical Trials

The cancer team at Adventist HealthCare recognizes the important role that clinical trials play in the study of new, innovative treatments or strategies that may lead to prevention, earlier detection, better treatments or cures for conditions such as cancer. Our expert cancer research team includes physicians and clinical research nurses as well as research associates and assistants who are involved with more than 65 cancer studies each year.

Search or Browse Cancer Clinical Trials

Showing 1-10 of 24

Sorted By:


    Randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 versus Standard of Care in NSCLC patients with PD-L1 positive tumours.


    Study compares once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone.

  • BAX69391401

    Study evaluates the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination.

  • ERA 223

    Study to determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer.

  • IMpower 131

    Randomized, open-label study to evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel.

  • IMpower 150

    Randomized, open-label study will evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with carboplatin and paclitaxel.

  • JAVELIN Solid Tumor

    Phase 1, open-label, dose-escalation trial of avelumab with consecutive parallel group expansion in subjects with selected tumor indications.

  • KEYNOTE191

    Study to characterize the safety and efficacy of ACP 196 monotherapy and ACP-196 plus pembrolizumab in subjects with recurrent ovarian cancer.

  • MK-3475-052/KEYNOTE-52

    Study uses pembrolizumab for first-line treatment of participants with advanced/unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy.

  • MK-3475-158/KEYNOTE-158

    In this study, participants with multiple types of advanced solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

Page of 3, showing trials 1-10 of 24

Clincal Trials & Research Studies

Patient Stories

We’re writing new chapters in the lives of our patients, their families and our community daily. These are their stories:

Local Health News - In Your Inbox

Join over 40k of your friends & neighbors and get the latest news about community health programs and events when you sign-up for Adventist HealthCare & You Digital.

Subscribe Today!